Median progression-free survival was significantly longer in the afatinib group ( 110 months , 95 % CI 97-137 ) than in the gemcitabine and cisplatin group ( 56 months , 51-67 ; hazard ratio 028 , 95 % CI 020-039 ; p < 00001 ) .